Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Min Yuen Teo

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2023
Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World ExperienceBrendan J Guercio, Michal Sarfaty, Min Yuen Teo, et al.
Cell Reports|December 21, 2022
Genomic heterogeneity as a barrier to precision oncology in urothelial cancerTimothy N Clinton, Ziyu Chen, Hannah Wise, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 4, 2024
Differential NEUROD1, ASCL1, and POU2F3 Expression Defines Molecular Subsets of Bladder Small Cell/Neuroendocrine Carcinoma With Prognostic ImplicationsDilara Akbulut, Karissa Whiting, Min-Yuen Teo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2026
Neoadjuvant nivolumab with or without ipilimumab for cisplatin-ineligible patients with muscle-invasive bladder cancerBrendan J Guercio, Eugene J Pietzak, Vignesh Ravichandran, et al.
Nature Communications|September 10, 2025
Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancerKevin Chang, Henry M Delavan, Elizabeth Yip, et al.
Clinical Genitourinary Cancer|June 8, 2022
Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant ChemotherapyMin Yuen Teo, Brendan J Guercio, Arshi Arora, et al.
JCO Precision Oncology|June 22, 2022
Clinical and Genomic Characterization of Bladder Carcinomas With Glandular PhenotypeNima Almassi, Karissa Whiting, Antoun Toubaji, et al.
European Urology|April 27, 2025
Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial CarcinomaCarissa E Chu, Ziyu Chen, Karissa Whiting, et al.
JCO Precision Oncology|May 1, 2024
Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder CancerAndrew T Lenis, Karissa Whiting, Vignesh Ravichandran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2022
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II TrialSamuel A Funt, Michael Lattanzi, Karissa Whiting, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2023
Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World ExperienceBrendan J Guercio, Michal Sarfaty, Min Yuen Teo, et al.
Cell Reports|December 21, 2022
Genomic heterogeneity as a barrier to precision oncology in urothelial cancerTimothy N Clinton, Ziyu Chen, Hannah Wise, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 4, 2024
Differential NEUROD1, ASCL1, and POU2F3 Expression Defines Molecular Subsets of Bladder Small Cell/Neuroendocrine Carcinoma With Prognostic ImplicationsDilara Akbulut, Karissa Whiting, Min-Yuen Teo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2026
Neoadjuvant nivolumab with or without ipilimumab for cisplatin-ineligible patients with muscle-invasive bladder cancerBrendan J Guercio, Eugene J Pietzak, Vignesh Ravichandran, et al.
Nature Communications|September 10, 2025
Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancerKevin Chang, Henry M Delavan, Elizabeth Yip, et al.
Clinical Genitourinary Cancer|June 8, 2022
Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant ChemotherapyMin Yuen Teo, Brendan J Guercio, Arshi Arora, et al.
JCO Precision Oncology|June 22, 2022
Clinical and Genomic Characterization of Bladder Carcinomas With Glandular PhenotypeNima Almassi, Karissa Whiting, Antoun Toubaji, et al.
European Urology|April 27, 2025
Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial CarcinomaCarissa E Chu, Ziyu Chen, Karissa Whiting, et al.
JCO Precision Oncology|May 1, 2024
Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder CancerAndrew T Lenis, Karissa Whiting, Vignesh Ravichandran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2022
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II TrialSamuel A Funt, Michael Lattanzi, Karissa Whiting, et al.
Pageof 5